1. A topical medicine for reducing at least one symptom of at least one dermatological condition containing acitretin in the form of a nanosuspension. A topical medicine for reducing at least one symptom of at least one dermatological condition containing at least 0.25% by weight of acitretin, said drug showing a release rate of at least 0.01 mg / cm2 min, measured with in vitro release measurement systems - Franz diffusion cell - under the following conditions: receptor medium containing 1% DMSO in (35% ethanol: 65% phosphate buffer with pH 8), speed 700 rpm, polysulfone membrane 0.45 μm, dosage300 ± 30 mg, temperature 32.5 ± 0.5 ° C. 3. The medicament according to claim 2, comprising a stable nanosuspension of acitretin. The medicament according to claim 3, characterized in that said medicament is a gel. The medicament according to claim 3, characterized in that acitretin is essentially amorphous. The medicament according to claim 3, characterized in that the diameter for at least 90% of the volume distribution of particles according to the laser diffraction technique is 1 micron or less. The medicament according to claim 3, characterized in that the diameter of at least 98% of the particles of acitretin is 1 micron or less. The medicament according to claim 3, characterized in that the diameter of at least 99% of the particles of acitretin is 1 micron or less. The medicament according to claim 3, comprising a copolymer of vinyl pyrrolidone and vinyl acetate. The drug according to claim 3, containing powder1. Лекарственное средство для местного применения для уменьшения по меньшей мере одного симптома по меньшей мере одного дерматологического состояния, содержащее ацитретин в виде наносуспензии.2. Лекарственное средство для местного применения для уменьшения по меньшей мере одного симптома по меньшей мере одного дерматологического состояния, содержащее не менее 0,25% масс, ацитретина, причем указанное лекарственное средство демонстрирует скорость высвобождения не
